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 Abstract 
 
BACKGROUND: One of the mechanisms that ensure cancer robustness is tumor 
heterogeneity, and its effects on tumor cells dynamics have to be taken into account when 
studying cancer progression. There is no unifying theoretical framework in mathematical 
modeling of carcinogenesis that would account for parametric heterogeneity.  
RESULTS: Here we formulate a modeling approach that naturally takes stock of 
inherent cancer cell heterogeneity and illustrate it with a model of interaction between a 
tumor and an oncolytic virus. We show that several phenomena that are absent in 
homogeneous models, such as cancer recurrence, tumor dormancy, an others, appear in 
heterogeneous setting. We also demonstrate that, within the applied modeling framework, 
to overcome the adverse effect of tumor cell heterogeneity on cancer progression, a 
heterogeneous population of an oncolytic virus must be used. Heterogeneity in 
parameters of the model, such as tumor cell susceptibility to virus infection and virus 
replication rate, can lead to complex, time-dependent behaviors of the tumor. Thus, 
irregular, quasi-chaotic behavior of the tumor-virus system can be caused not only by 
random perturbations but also by the heterogeneity of the tumor and the virus. 
CONCLUSIONS: The modeling approach described here reveals the importance of 
tumor cell and virus heterogeneity for the outcome of cancer therapy. It should be 
straightforward to apply these techniques to mathematical modeling of other types of 
anticancer therapy.  
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 BACKGROUND 
 
Cancers are extremely complex systems that possess many features of robustness, 
i.e., they are systems that tend to maintain stable functioning despite various 
perturbations [1, 2]. The main two mechanisms that enable cancer robustness are 
functional redundancy, that comes from inherent heterogeneity of tumor cells, and 
feedback-control systems that facilitate survival of a tumor under adverse conditions,  
e.g., caused by anticancer drugs [3-6]. Many approaches to anticancer treatment have had 
limited success due to cancer robustness. An important challenge is to identify fragilities 
of cancers as robust biological systems and develop treatment strategies that take 
advantage of these weak links. Thus, a better understanding of the mechanisms that yield 
cancer robustness, particularly, functional redundancy, is vital.  
Redundancy in cancers occurs at two levels. First, multiple copies of identical 
cells increase the likelihood of restoration of a tumor after treatment. Second, functional 
redundancy can be mediated by functionally equivalent but heterogeneous components 
(known as heterogeneous redundancy). Heterogeneous redundancy is thought to be 
central to tumor robustness. Although heterogeneity is a well-recognized characteristic of 
tumors that can lead to drug resistance, the current body of experimental and clinical data 
that relate to dynamic changes in intratumoral heterogeneity during progression, as well 
as to responses to various therapeutic strategies, is insufficient [2]. 
The term ‘tumor heterogeneity’ means the existence of distinct subpopulations of 
tumor cells with specific characteristics within a single neoplasm [7, 8]; in particular, 
surviving subpopulations of cells with metastatic potential after anticancer therapy can 
lead to tumor recurrence [9-11]. Tumor heterogeneity is a well documented phenomenon 
[3] as demonstrated  by extensive cytogenetic analysis [12, 13]. Furthermore, many 
tumors are characterized by heterogeneous, often, non-random, spatio-temporal 
distribution of genetically heterogeneous tumor cells [4]. Distinct subpopulations of cells 
have been isolated from experimental and human neoplasms of every major histological 
type and location. These subpopulations are heterogeneous for many characteristics, such 
as morphology, growth rate, metastatic potential, karyotype, antigenicity, 
immunogenicity, biochemical properties, sensitivity to chemotherapeutic agents and 
radiation, etc. Genetic heterogeneity is, arguably, a major cause of acquired drug 
resistance of tumors [14, 15].  
The dynamics of host-tumor system, which entails co-evolution under the 
selective pressure that is imposed by host environments, including antitumor drugs, is 
highly complex and nonlinear. Thus, to precisely define the conditions for successful 
therapy, mathematical models are needed. Extensive efforts have been dedicated over 
many years to mathematical modeling of cancer development and anticancer therapy. 
Stochastic models that take into account random mutations and cell proliferation proved 
to be useful in the context of epidemiology and statistical data [16], and for modeling 
cancer initiation and progression in terms of somatic evolution [17]. Deterministic 
models of tumor growth have proved valuable as well. Many of these have addressed 
avascular and vascular tumor growth taking advantage of methods borrowed from 
physics [18] but some use models from population biology to treat a tumor as a dynamic 
society of interacting cells [19-21]. A variety of mathematical approaches contribute to 
modeling cancer progression from different standpoints and take stock of various factors 
affecting tumor growth [22 and references therein, 23]. Combined analysis of tumor 
growth and anticancer therapies within the framework of mathematical modeling also 
produced a number of significant results [24, 25]. 
Inasmuch as tumor heterogeneity is one of the crucial factors in determining 
possible outcomes of anticancer treatment, it has to be incorporated and investigated in 
mathematical models. Although heterogeneity of tumor cell populations has been widely 
studied, there is no general approach that would provide a comprehensive description of 
intrinsic heterogeneity of tumors and would be amenable to qualitative and quantitative 
mathematical analysis. The existing mathematical models of anticancer therapy either do 
not include the effects of heterogeneity [e.g., 26, 27], or consider finite, usually, small, 
number of subpopulations, e.g., sensitive and resistant cells or proliferating and quiescent 
cells [e.g., 28, 29]. Other models take into account only spatial heterogeneity and do not 
address the important subject of genetic heterogeneity [e.g., 30, 31, 32], or use 
individual-based approach and simulation techniques and thus are, practically, not 
amenable to analytical mathematical analysis [e.g., 33, 34, 35]. 
The main goal of the present paper is to introduce a novel approach to model 
heterogeneity into the field of cancer modeling. We show that heterogeneous models, 
although still oversimplified, reflect qualitatively new phenomena, some of which are 
observed in experiments and clinical trials. We present an effective method to analyze 
these models and examine the predictions that such heterogeneous models can yield.  
We illustrate our approach by addressing a complex process that involves both 
virus-cell interaction and tumor growth, namely, the interaction of the so-called oncolytic 
viruses with tumors. Oncolytic viruses are viruses that specifically infect and kill cancer 
cells but do not affect normal cells [36-39]. Many types of oncolytic viruses have been 
studied as candidate therapeutic agents, including adenoviruses, herpesviruses, 
poxviruses, reoviruses, paramyxoviruses, and retroviruses [37, 39]. Probably, the best-
characterized oncolytic virus, that has drawn much attention, is ONYX-015, an 
attenuated adenovirus that selectively infects tumor cells with a defect in the p53 gene 
[38, 40]. This virus has been shown to possess substantial antitumor activity and has 
proven relatively effective at reducing or eliminating tumors in clinical trials [41-43]. 
Although safety and efficacy remain major concerns, several other oncolytic viruses 
acting on different principles, including tumor-specific transcription of the viral genome, 
have been developed, and some of these viruses have entered or are about to enter clinical 
trials [37, 44-47]. Recently, synergistic use of immune therapy and oncolytic viruses has 
shown particular promise in cancer treatment [48].  
The oncolytic effect can result from at least three distinct modes of virus-host 
interaction [37, 39]. The first mode involves repeated cycles of viral replication in the 
tumor cells leading to cell death and, consequently, to tumor reduction and, potentially, 
elimination. The second mode involves low-level virus reproduction that, however, 
results in the production of a cytotoxic protein that causes cell damage. The third mode 
consists in induction of antitumor immunity by virus infection of cancer cells. Cancer 
cells possess weak antigens for host immune sensitization. Virus infection causes 
inflammation and lymphocyte penetration into the tumor, with the virus antigens eliciting 
increased sensitivity to tumor necrosis factor-mediated killing.  
Although the indirect modes of virus cancer therapy based on production of 
cytotoxic proteins or antitumor immunity might be promising, direct lysis of tumor cells 
by an oncolytic virus is the current mainstream strategy. Experiments on human tumor 
xenografts in nude mice have shown that the effect of oncolytic virus infection on tumors 
can range from no apparent effect, to reduction and stabilization of the tumor load (i.e., 
the overall size of a tumor), to elimination of the tumor [49]. Complete regression of 
tumors has been reported also in some patients treated with oncolytic viruses as part of 
clinical trials [50]. In a previous study [51], we presented a conceptual mathematical 
model of tumor cells-virus interaction which, depending on system parameter values, 
exhibits various behaviors including deterministic elimination of the cancer cells. Here, 
we further examine this model in conjunction with different possible heterogeneities of 
tumor cells, such as different susceptibility to infection, different death rates of infected 
cells, and others. 
 
 
RESULTS 
 
Homogeneous mathematical models (phase-parameter portrait) 
In this section, we briefly present the main results of the analysis of a simple 
conceptual model of virus-tumor interaction [51]; these will be important for the further 
analysis described in the present work. The model allows for two populations of cells: 
uninfected tumor cells and infected tumor cells and is an extension of the previous work 
of Wodarz [52] to include an alternative non-linear functional response for infection rate.   
 The model, which considers two types of cells growing in the logistic fashion, has 
the following form: 
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where X  is the size of the uninfected cell population; Y  is the size of the infected cell 
population;  and  are the maximum per capita growth rates of uninfected and infected 
cells respectively; 
1r 2r
K  is the carrying capacity; b  is the transmission coefficient (this 
parameter also includes the replication rate of the virus); and  is the rate of infected cell 
killing by the virus (cytotoxicity). All the parameters of the model are supposed to be 
non-negative. Model (1) is subject to initial conditions 
a
0)0( 0 >= XX  and . 
The concentration of viral particles is not explicitly included; it is assumed that virus 
abundance is proportional to infected cell abundance [53]. 
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trtKtYtYKtXtX 1
*****    ,/)()(   ,/)()( ===
 
 
,))(1(
   ,))(1(
*
**
**
***
*
*
**
**
***
*
*
Y
YX
YXYXY
dt
dY
YX
YXYXX
dt
dX
δβγ
β
−+++−=
+−+−=           (2) 
 
where 1/ rb=β , 12 / rr=γ , and 1/ ra=δ . In the following analysis, we suppress the 
asterisks to simplify the notations, but it should be clear that we use non-dimensional 
parameters and scaled sizes of cell populations, so that 1≤+YX  for any t . 
The complete phase-parameter portrait of system (2) is shown in Fig. 1. 
The model (2) exhibits all possible outcomes of oncolytic virus infection, i.e., no 
effect on the tumor (domains I and II in Fig. 1), stabilization or reduction of the tumor 
load (domains IV and V), and complete elimination of the tumor (domain VIII). Moreover 
there are two domains (domains III and VII) where the final outcome crucially depends 
on the initial conditions and can result either in failure of virus therapy or in stabilization 
(domain III) and elimination (domain VII) of the tumor.  
 
Heterogeneous model 
 
General consideration 
 
The model (1) consists of two coupled, deterministic differential equations 
allowing for cell reproduction and death, and cell infection. This model is one of the 
mathematical models of tumor growth that treat a tumor as a dynamic society of 
interacting cells (e.g., [19, 20, 22]). Most population models suppose that all individuals 
have identical attributes, in particular, identical rates of growth, death and birth. This 
assumption simplifies computation, albeit at the cost of realism.  
There are different ways to model heterogeneity. If it is assumed that 
heterogeneity of population is mediated by a structured variable (such as explicit space or 
age), we have to deal with partial differential equations (PDEs) (for application of space 
explicit models to tumor-virus interaction, see [54] and references therein; cell age is 
modeled, e.g., in [55]). By contrast, here, we explore heterogeneity of parameters (such 
as birth and death rates, and infection rate), i.e., we consider parameters as inherent and 
invariable properties of individuals, whereas parameter values can vary between 
individuals; any changes of mean, variance and other characteristics of the parameter 
distribution with time are caused only by variation of the population structure. This type 
of heterogeneity has been designated ‘parametric’ by Dushoff [56]. 
The most common method to take account of parametric heterogeneity is to 
divide a population into groups [28, 57, 58]. An important disadvantage of this approach 
is that heterogeneity within a group cannot be incorporated. Another approach is to 
consider the population as having a continuous distribution of parameters [59-62]. In the 
latter case, one usually has to deal with infinite-dimensional dynamical systems but, in a 
wide range of specific cases, there is an efficient analytical theory that allows one to 
reduce an initial distributed system to a system of ordinary differential equations (ODEs) 
[61, 62] (see also Mathematical Appendix). Here, we adopted this approach and 
emphasize that the applied reduction permits us to follow not only the total sizes of the 
populations, but also the time-dependent dynamics of the distributions, i.e., no 
information is lost when we switch from infinite-dimensional dynamical system to 
system of ODEs. It should be further emphasized that this reduction is not an 
approximation but results in an equivalent model, in contrast to the approaches 
commonly used to solve similar systems numerically [59, 63, 64]. 
 The starting point of our analysis is the model (2) which is a non-dimensional 
version of the initial model (1). As a matter of fact, by assuming that one or more 
parameters are distributed through the populations of cells, we have to deal with the 
initial system (1) with dimensional parameters. However, the two parameters that are of 
particular interest are transmission coefficient  and cytotoxicity , and in the 
following, we assume that these parameters (or either of them) are distributed, whereas 
the net growth rates and carrying capacity are supposed to be the same for all tumor cells.  
Since non-dimensional parameters 
b a
β  and δ  differ from  and  only by linear scaling, 
the system with distributed non-dimensional parameters 
b a
β  and δ  can be analyzed 
without loss of generality. 
  
Distributed susceptibility 
 
Let us assume that transmission coefficient β  is distributed through the 
population of uninfected tumor cells. Denote Β  the set of possible values of β  and 
),( βtx  the density of uninfected cells that have a given value of β  at moment t  (i.e., for 
any subset Β⊆Β~ , the part of the population with trait values belonging to  is given by 
, and the total size of the population, , is given by ).  
Β~
∫Β~ ),( ββ dtx )(tX ∫Β ββ dtx ),(
The number of uninfected cells with a given value ofβ  that become infected per 
time unit is given by ),( βρ tx , where ),,( YXβρρ =  is the rate of infection. We assume 
that this function depends only on the value of β  and the total sizes of the infected and 
uninfected cell subpopulations. This assumption reflects the fact that different cells can 
have different susceptibilities to virus infection, i.e., some of them can be infected with a 
relatively high probability whereas others are infected with a low or even zero 
probability; the latter case corresponds to the situation when a particular subpopulation of 
tumor cells cannot be reached by the virus.  
Using the nonlinear transmission function in (2) we obtain that the change in 
subpopulation of uninfected cells with parameter value β  is given by 
))()(/()(),( tYtXtYtx +ββ . We also need to specify the law of growth of tumor cells with 
a fixed value ofβ . Let us assume that uninfected cells with a particular value ofβ  beget 
daughter cells with the same parameter value. For the net growth rate, we use the logistic 
law that depends on the total population sizes, X  and Y . We do not consider 
heterogeneity in the infected cell population, and, hence, the total amount of newly 
infected cells per time unit is given by ))()((),()( tYtXdtxtY +∫Β βββ , which should be 
taken into account when writing down the equation for the change in the infected cell 
population. By specifying initial conditions for ),( βtx  and , we obtain the model in 
the form 
)(tY
 
 
[ ]
[ ] ),(
)()(
)()()(
))()((1)()(
,
)()(
)(),())()((1),(),(
tY
tYtX
tYtXtE
tYtXtY
dt
tdY
tYtX
tYtxtYtXtx
t
tx
δγ
ββββ
β −+++−=
+−+−=∂
∂
          (3) 
 
where the following notation was used: ( ) )(),()( tXdtxtE ∫Β= ββββ .  
The initial conditions are  
 
 000 )0(     ),,0()(),0( YYpXxx === βββ .           (4) 
 
Here )(0 βx  is the initial distribution of β  in the population of uninfected cells,  is 
the total number of uninfected cells at the initial moment, and 
0X
),0( βp  is the probability 
density function (pdf) of the initial distribution of β .  Note that  can be rewritten 
in the form , where 
)(tEβ
∫Β= ββββ dtptE ),()( ),( βtp  is the pdf of the distribution of β  at 
time t , and, thus,  is the mean value of )(tEβ β  at moment t . 
 Integrating the first equation in (3) over β  we obtain the system 
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where we suppressed the dependence of phase variables on t , and the initial conditions 
are . In order to solve this system, we only need to know the explicit 
expression for . If we use the usual notation  
00 )0(,)0( YYXX ==
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for the moment generation function (mgf) of the initial pdf, it can be shown ([61, 62], see 
also Mathematical Appendix) that the current mean value of β  can be calculated using 
the mgf of the initial distribution of β ; the exact expression is 
 
)(
)(
))((
1)(
tq
d
dM
tqM
tE
=
=
λ
β
β
β λ
λ
, 
 
where  is an auxiliary variable that satisfies the equation )(tq
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and )(λβM  is given as far as we specify the initial pdf ),0( βp . 
In other words, model (3)-(4) is equivalent to the system of ODEs (5)-(6), which 
can be analyzed in the usual way; moreover, it is very easy to solve this system 
numerically (there are methods to obtain the solution of (3)-(4), e.g., [59], but these 
methods are usually computationally intensive and not so effective as numerical methods 
for ODEs). 
Note that system (5) differs from (2) only by the time-dependent coefficient 
. In a number of cases, it is straightforward to determine the asymptotic behavior of 
 (i.e., when ), and in this situation, we can use the theory of asymptotically 
autonomous differential equations to infer the final outcome of the cell dynamics using 
the parametric portrait (e.g., [65]). More importantly, however, the simultaneous 
)(tEβ
)(tEβ ∞→t
knowledge of the time dependence of  and the parametric portrait of the 
homogeneous model (2) (Fig. 1) allows one to identify transient behavior of the solutions 
of (5) (and, accordingly, of model (3)), i.e., the behavior of solutions prior to the time 
moment when  becomes constant. This behavior can be of particular interest 
because this is one of the features that distinguishes model (3) from (2) and allows us to 
explore in detail the temporal dynamics of inhomogeneous biological systems. 
)(tEβ
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 Due to the non-negativity of β , we should consider only distributions with 
support on half-axis 0≥β . To illustrate the possible dynamical behavior of the cell 
populations, we need the initial distribution of β , which is unknown. In the following, 
we assume that the initial pdf of β  is the gamma distribution on ),[ ∞η  with positive 
parameters  and sk  , 0≥η . The choice of the gamma distribution can be justified by the 
fact that it can well approximate almost any unimodal distribution concentrated on the 
positive half-line. Other possible initial distributions include uniform, log-normal, Pareto, 
and many others; any of them can be incorporated in the model as far as there exist mgfs 
for the given  (we note, however, that, in some particular cases, mgf is not 
determined for any possible values of  (see Mathematical Appendix). 
)(tq
)(tq
For the case of gamma distributed β , it is straightforward to show (see 
Mathematical Appendix) that ))(/()( tqsktE −+=ηβ , and ηβ →)(tE  when ∞→t  
(because , see (6)). However, in a particular situation, we might not reach the 
final point because  can approach zero (see the equation for  in (6)). 
−∞→)(tq
)(tY )(tq
 In brief, we use the following approach to perform and present numerical 
simulations. First, we need to specify the initial conditions and the initial distribution of 
β , i.e., assign values of sk  , ,η . Here, for the sake of transparency, we have chosen to set 
the values of the mean  and variance  
 of the initial distribution, as well as the bounds of the 
distribution if they are different from zero or infinity (for the gamma distribution, the 
bound that has to be specified is its left boundary, 
∫Β= ββββ dpE ),0()0( =2βσ
22 )0(),0( ββββ Edp −∫Β
η ). In the analyzed case (when we 
work with the distribution that has two free parameters, k  and ), this is sufficient to s
unambiguously determine the values of the parameters (obviously, however, this is not 
the case in the general situation). 
 It can be shown that, for model (3)-(4), the mean of the parameter distribution 
decreases monotonically with time ( 0/)( <dttdEβ  for any t ) from the initial value 
 to the final value )0(βE η . Loosely speaking, during the simulation, the parametric point 
with coordinates ))(,,( tEβδγ  travels in the parameter space of model (2); the movement 
occurs along the line connecting points ))0(,,( βδγ E  and ),,( ηδγ  in the parameter 
portrait of (2) (see Fig. 1 for the cut of the parameter space for fixed γ ). The speed of 
movement is determined by the parameters of the initial distribution, or, equivalently, by 
the initial mean and variance of the gamma distribution with the given left boundary.  
 Results of several numerical simulations of system (5)-(6) are shown in Fig. 2. 
The parameter values were chosen such that we start in domain VIII (Fig. 1) (eradication 
of the tumor), cross domain VII (bistable situation), and end up in domain I (no effect of 
virus therapy). The solutions shown in Fig. 2 reflect the fact that the degree of 
heterogeneity plays an important role in the model dynamics. The parameter values and 
initial conditions are the same for all four simulations; the difference comes from 
different initial variances of β ; the greater the initial variance the faster we reach the 
unfavorable domain I. Conversely, the initial variance of the distribution can be small 
enough such that  the time during which the size of the tumor  remains negligible ( YX +  
is close to zero) is comparable with the life-time of a patient; this emphasizes that we 
need to know not only the final state of   but also its transient behavior. )(tEβ
 Fig. 2 shows the phenomenon of tumor recurrence after a relatively long period of 
small tumor load, a phenomenon that is not seen in the original homogeneous model (2). 
Clearly, reappearance of the tumor is a probable outcome of tumor-specific virus 
treatment if there are cancer cells that are inaccessible to the virus (or are accessible at an 
extremely slow rate compared to the characteristic time of virus propagation): after the 
virus kills off the susceptible tumor cells and is cleared (given that it cannot infect 
healthy tissues), these resistant cancer cells can develop into a new tumor. It should be 
emphasized that, in the simulations in Fig. 2, all the cells have non-zero probability to be 
infected ( 0>η ), but the final outcome is tumor recurrence, i.e., the tumor dynamics is 
strongly affected by cell heterogeneity. This example shows that heterogeneous model 
(3), together with dynamical regimes inherited from model (2), possesses new regimes, 
and, thus, is more general.  
 The change of the mean parameter value for the cases presented in Fig. 2 is shown 
in Fig. 3. It can be seen that higher rate of change corresponds to greater values of the 
initial variance; in addition, in none of the analyzed cases  reaches the final value )(tEβ
η , because the speed of movement is determined by two simultaneously acting factors: 
the characteristics of the mgf and the equation for the auxiliary variable  for which 
 starting  from some time .  
)(tq
0/)( ≈dttdq t
 Other possible cases can be similarly analyzed; for example, if we choose 
parameters such that the starting point belongs to domain IV (Fig. 1a) and the final point 
belongs to domain II, it is not difficult to predict that, first, there will be a short period of 
time when the tumor load remains constant, then the tumor starts growing linearly (when 
 belongs to domain V), and in domain II, the tumor grows under the logistic law 
(Fig. 4). Thus, accommodation of heterogeneity results in model dynamics that reflects 
the phenomenon of temporary dormancy of the tumor (Fig. 4). 
)(tEβ
 
Distributed susceptibility and distributed cytotoxicity 
 
 Together with differential susceptibility considered in the previous section, 
parameter δ  (the rate of killing of infected cells) also may be assumed to take different 
values in the infected cell population. The population of infected cells can be 
heterogeneous on its own such that some cells are more likely to die faster than others 
when infected by the virus. From different perspective, we can attribute this 
heterogeneity to the virus, i.e., the virus population is assumed to consist of strains that 
differ in their ability to kill cells. In previous work [51, 52], it has been shown that, in 
some parameter domains, there is an optimal level of cytotoxicity that is necessary to 
maximally reduce the tumor size if other parameter values are fixed. In addition, it is 
sometimes desirable to kill as many cells as possible during a short period of time; such 
situation would favor using different viruses for therapeutic purposes. Moreover, the 
latter assumption on heterogeneous virus can help one to interpret the model equations 
which, assuming that δ  takes values from set Δ , and ),( δty  is the density of infected 
cells having parameter value δ , take the form: 
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where  is defined as above, and the initial conditions are  )(tEβ
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 Note that in (7) both cell populations are closed under reproduction; that is, e.g., 
the uninfected cell that has parameter value  can produce daughter cells only with the 
same parameter value (the same holds for the infected cell population). At the same time, 
it follows from (7) that, if an uninfected cell was infected by the virus from an infected 
cell with the parameter value , it falls into the same class. If we assume that 
*β
*δ δ  is an 
attribute of the cell population, this assumption is difficult to justify, whereas if δ  is an 
attribute of the virus, the assumption follows from obvious considerations. 
 System (7)-(8) is equivalent to the following system of ODEs (see Mathematical 
Appendix): 
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where the mean parameter values are  
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for the given mgf of ),0( and ),0( 21 δβ pp , and the auxiliary variables can be found from 
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 To analyze system (9)-(10), one has to specify initial conditions and initial 
distributions for parameters β  and δ . As before, to obtain some insight into the possible 
dynamical behavior of (9), we can consider the parameter portrait (Fig. 1) and time-
dependent changes of the mean parameter values. In the case under consideration , 
as before, moves from top to bottom in Fig. 1, whereas  goes from right to left. 
Note that the speed of movement in the 
)(tEβ
)(tEδ
δ -direction is determined only by the properties 
of the mgf, because  from (10) and  does not depend on the population 
sizes. 
ttq −=)(2 )(2 tq
Generally, the transient behavior of cell populations (prior to reaching the final 
state – if it is ever reached) can be quite complex. This can be seen in Fig. 4 where the 
solutions of (9)-(10) are shown (Fig. 5a), and the path of the mean parameter values 
depicted (Fig. 5b). Due to the structure of the parametric portrait of (2), the mean 
parameter values can pass through domains of qualitatively different behavior many 
times, thus resulting in complex and unpredictable picture. Moreover, even if the initial 
and final parameter points belong to the same domain, during transient process, the mean 
parameter values can visit other domains (Fig. 6). 
 In Fig. 6, the initial and final parameter values belong to the most favorable 
domain VIII (Fig. 1), in which complete eradication of the tumor cells occurs. On its way 
to extinction, however, the tumor load behaves in an irregular, complex way. This 
example shows the possibility that complex and erratic observational data can be 
explained not only by random effects and noise but also by the innate heterogeneity of 
the cell and virus populations. 
 In general, both distributed susceptibility of uninfected cells and distributed 
cytotoxicity of the virus do not favor the tumor treatment and decrease chances for 
effective cure by increasing tumor robustness; one of the possible ways to overcome this 
problem (within the framework of the considered models) is suggested in the next 
section. 
 
Distributed susceptibility and distributed virulence  
 
 The inherent heterogeneity of tumor cells implies that cells differ in their 
susceptibility to virus infection, and this situation was modeled in two previous sections. 
In general, it can be assumed that the virus population is also heterogeneous in the sense 
that it contains virus strains with different ability to infect tumor cells. Inasmuch as 
model (1) does not explicitly model the virus dynamics, we can incorporate the effect of 
virus heterogeneity into the infected cell population, and, hence, consider the 
transmission coefficient β  as the product of the susceptibility of uninfected cells 1β  and 
the virus replication rate 2β . 
As before, denote  the set of possible values of 1Β 1β  and ),( 1βtx  the density of 
uninfected cells having the given value of 1β  at the moment t ; similarly, denote  the 
set of possible values of 
2Β
2β  and ),( 2βty  the density of uninfected cells with the given 
value of 2β  at the time moment t . The number of cells with susceptibility 1β  newly 
infected by the virus produced from previously infected cells with replication rate 2β  is 
given by ))()(t/(),(),( 2121 tYXtytxβ β β +β . The total number of cells that leave the 
uninfected population and have susceptibility 1β  is 
; and the total change in the infected cell 
population with virus replication rate 
))()(/(),(),( 22211
2
tYtXdtytx +∫Β βββββ
2β  due to the infection process is given by 
. Combining the above assumptions, we obtain 
the model 
))()(/(),(),( 11122
1
tYtXdtxty +∫Β βββββ
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where the notations )(),()(  ),(),()(
21
22221111
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were used for the current mean values of the corresponding parameters, and the initial 
conditions are 
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The model (11)-(12) is equivalent to the system of ODEs 
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where the mean parameter value is ),()()(
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are expressed with the mgfs of ),0(),,0( 2211 ββ pp . The auxiliary variables can be found 
from the equations 
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  As before, we have to specify the initial pdfs for 1β  and 2β . Now we have 
, and it can be shown that , that is, formally, the movement 
in the
0/)(2 ≥dttdq 0/)(2 ≥dttdEβ
2β -direction goes from smaller to greater mean values. In order not to deal with an 
infinitely large coefficient, it is reasonable to assume that the initial distribution of 2β  is 
determined on a closed interval . In this case, we can choose as the initial 
distribution the beta distribution on . 
],[ 21 cc
],[ 21 cc
To get insight into the transient behavior of the model solutions, we have to 
consider the product of the mean parameter values. Again, we move along the line in 
the β -direction (Fig. 1), starting from , with the asymptotic state )0()0(
21 ββ EE 2cη . The 
important difference now is that the function  does not have to be monotonic (Fig. 
7). 
)(tE
 In Fig. 7, the results of numerical simulation of system (13)-(14) are shown 
together with functions ,  and )(
1
tEβ )(2 tEβ )()()( 21 tEtEtE ββ= . We start in domain 
VIII (elliptic sector in Fig. 1), and the asymptotic state is in domain VII where two 
opposite outcomes are possible, namely, complete tumor eradication or logistic tumor 
growth. The initial conditions and parameter values are the same for both cases; the two 
cases differ only in the initial variance of the 2β  distribution. It can be seen from Fig. 7 
that even a small difference in the variance of 2β  may yield dramatically different 
results: in the first case, the tumor is cured, whereas, in the second case, virus therapy 
fails. This example emphasizes that, to predict the outcome of oncolytic virus therapy, it 
is necessary to know not only the initial sizes of the cell populations but also the degree 
of heterogeneity of all the parameters under consideration, in particular, the virus 
replication rate.   
 
 
Discussion and conclusions  
  
We presented a general framework within which to construct and analyze 
mathematical models of anticancer treatment, with a special emphasis on tumor 
heterogeneity. Conceptually, this approach is connected to the theoretical considerations 
of Kitano on cancer robustness [1, 2]. At this initial step of analysis, it appears most 
important that the mathematical models reproduce important behaviors of tumors at the 
qualitative level. Using the previously developed model of tumor cell-oncolytic virus 
interaction [51], we show that qualitatively distinct  behaviors that are absent in the 
homogeneous model appear as natural consequences of tumor and oncolytic virus 
heterogeneity. For example, our model accounts for cancer recurrence, and the time until 
reappearance of the tumor crucially depends on the heterogeneity of the transmission 
coefficient (Fig. 2). It should be emphasized that the effects of the tumor cell 
heterogeneity are not limited to trivial resistance of a subpopulation of cells to the virus, 
i.e., recurrence might ensue even when all cells have a non-zero probability to be 
infected. Another phenomenon missing in the homogeneous model is constant tumor size 
during a particular period of time (Fig. 4). Heterogeneity in parameters can lead to 
complex, time-dependent behaviors of the tumor (Fig. 5 and 6). Thus, interpretation of 
the results of anticancer therapy should take into account the possibility that irregular, 
quasi-chaotic behavior can be caused not only by random fluctuations but also by the 
heterogeneity of the tumor and the virus (Fig. 6). All the simulations presented here 
reveal the effect of the level of heterogeneity on tumor dynamics. The most obvious case 
is shown in Fig. 7 where different initial variances of parameter distribution lead either to 
tumor eradication or to logistic tumor growth, i.e., failure of virus therapy. 
Analysis of the models proves that tumor heterogeneity increases cancer 
robustness, in agreement with the theoretical considerations of Kitano [2]. The results 
presented here further show that, to counter this adverse effect of tumor heterogeneity, it 
should be possible to employ a heterogeneous population of an oncolytic virus (see 
model (11) and Figure 7). The interaction of the two non-homogeneous populations, the 
tumor and the oncolytic virus, may result in complete elimination of the tumor.  
We applied a previously developed, general mathematical technique [61, 62] to 
investigate non-homogeneous models of complex tumor cells-virus interaction. The 
advantages of this modeling approach are as follows. This approach can account for 
different types of parametric heterogeneity of the analyzed populations. To infer the 
consequences of heterogeneity, we use well-known mathematical tools, such as 
bifurcation analysis, which identifies points of qualitative change in system dynamics. 
The theory of heterogeneous populations [61, 62, 66] allows one to reduce the models to 
systems of ODEs that, in many cases, can be explored analytically or, if this is not 
possible, can be solved numerically with high precision.  
Cancer is an evolving system, and the main evolutionary forces are selection, 
mutation and random drift. It should be noticed that our approach explicitly examines 
only selection. The techniques is applied to deterministic systems, and it is our belief that 
such system are important for modeling purposes, although analysis of extinction 
phenomena, such as tumor eradication, may require stochastic factors to be considered. 
The principal obstacle to the validation of these models against empirical data and their 
use for prediction purposes is the necessity to know the initial distribution of the model 
parameters. It should be emphasized that knowledge of mean, variance, and any finite 
number of the moments of the distribution is not sufficient to describe the evolution of 
the system over indefinite time [62]. The entire distributions have to be known. However, 
there is a way to bypass this problem. First, knowledge of several first moments is 
sufficient to estimate tumor evolution over short time spans. Second, to model the 
evolutionary process, we need to know how the mean parameter values behave with time. 
Using the theory of heterogeneous populations, we can infer generic properties of these 
functions and identify them from empirical data [67].  
To conclude, the approach developed here allows one to take stock of such a 
complex aspect of cancer as tumor heterogeneity and apply effective analytical 
techniques to the analysis of heterogeneous models of tumor evolution. Although, in this 
study, we analyzed the specific case of a tumor interaction with an oncolytic virus, it is 
our hope that these techniques will prove useful in other systems that include interaction 
between tumor cells and anticancer agents.  
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Fig. 1. Phase-parameter portrait of system (2) given as a cut of the positive parameter 
space ),,( δβγ  for an arbitrary fixed value of 10 << γ  (a) and γ<1  (b). The boundaries 
of domains are { }0  : ),,( 1 =−= βδγβδα  , { }0   : ),,( 2 =−= δγγβδα , { }0   : ),,( 3 =−= δγβγβδα , and { } 01  : ),,( 4 =+−−= βδγγβδα . 
 
 
Fig. 2. Solutions of system (5)-(6) with gamma distributed parameter β  on ),5.1[ ∞ . 
Uninfected cells, , infected cells, , and the total tumor load, , are 
shown in blue, green and black, respectively. The initial conditions 
, parameter values 
)(tX )(tY )()( tYtX +
1.0)0(  ,5.0)0( == YX 2  ,1 == δγ . The initial mean of distribution 
, the initial variances 0.06 (a), 0.1(b), 0.3(c), 0.4(d). 5.2)0( =βE
 
 
Fig. 3.  versus time for the cases presented in Fig. 2. The curves from top to bottom 
correspond to panels (a)-(d) in Fig. 2.  
)(tEβ
 
 
Fig. 4. Solutions of system (5)-(6) with gamma distributed parameter β  on ),1.0[ ∞ . 
Uninfected cells, , infected cells, , and the total tumor load, , are 
shown in blue, green, and black, respectively. The initial conditions are 
, parameter values 
)(tX )(tY )()( tYtX +
1.0)0(  ,5.0)0( == YX 3.0  ,5.0 == δγ . The initial mean of 
distribution , the initial variances 1.5 (a) and 0.5(b). 5.3)0( =βE
 
 
Fig. 5.  (a) Solutions of system (9)-(10) with gamma distributed parameters β  on ),1[ ∞  
and δ  on . Uninfected cells, , infected cells, , and the total tumor load, 
, are shown in blue, green and black, respectively. The initial means of the 
distributions are  and 
),1[ ∞ )(tX )(tY
)()( tYtX +
11)0( =βE 10)0( =δE , initial variances are  and 
. The initial conditions are 
8)0(2 =βσ
5.0)0(2 =δσ 1.0)0(  ,5.0)0( == YX , and 1=γ . (b) The 
parametric curve ( ))(),( tEtE δβ  in the parameter space (compare with Fig. 1b)  
 
 
Fig. 6. (a) Solutions of system (9)-(10) with gamma-distributed parameters β  on ),2[ ∞  
and δ  on . Uninfected cells, , infected cells, , and the total tumor load, 
, are shown in blue, green and black, respectively. The initial means of 
distributions are  and 
),9.0[ ∞ )(tX )(tY
)()( tYtX +
11)0( =βE 10)0( =δE , initial variances are  and 
. The initial conditions 
8)0(2 =βσ
5.0)0(2 =δσ 1.0)0(  ,5.0)0( == YX  and 7.0=γ . (b) The 
parametric curve ( ))(),( tEtE δβ  in the parameter space 
 
 
Fig. 7.  Solutions of system (13)-(14) with both uninfected cell specific and infected cell 
specific distributions of transmission coefficient β . 1β  is gamma-distributed on ),6.0[ ∞  
and 2β  is beta-distributed on . Uninfected cells, , infected cells, , and 
the total tumor load, , are shown in blue, green and black, respectively. The 
initial means of distributions are 
]5.2 ,0[ )(tX )(tY
)()( tYtX +
9.2)0(
1
=βE  and 6.0)0(2 =βE , initial variances are 
 and  (a)  (b). In panels (c) and (d), the mean 
parameter values ,  and 
9.1)0(2
1
=βσ 12.0)0(22 =βσ 11.0)0(22 =βσ
)(
1
tEβ )(2 tEβ )()()( 21 tEtEtE ββ=  are shown for cases (a) and 
(b), respectively  
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Mathematical Appendix 
 
On Mathematical Theory of Inhomogeneous Community Models  
 
 Let us consider a model of a community consisting of m interacting populations in 
the general form 
 
 dN j/dt = N jF j(N,a),   j=1,…m,                     
 
where N j is the size of j-th population, N=(N1, …,N m). The growth rate F j can depend on 
parameters and a=(a1,a2,…as) is the vector-parameter with the domain A. We suppose 
here that every individual is characterized by its own value of vector-parameters a. Let 
lj(t,a)  be the density of the j-th population along the vector-parameter a at time t. In [1-4] 
the following model of an inhomogeneous community was explored: 
 
 dl j(t,a)/dt = F j(N,a) l j(t,a),                                             (A.1) 
 N j(t) = l ∫
A
j(t,a)da .                                                         
 
We suppose here that the fitness of individuals in the j-th population, defined by the 
formula Fj(N,a)=[dl j(t,a)/dt]/l j(t,a), depends on the parameter a and on total sizes of all 
subpopulations but not on the parameter distribution inside the subpopulations.  
This type of models can well describe, e. g., cooperative dynamics of populations 
or resource-consumer model of inhomogeneous community, but are not applicable to 
prey-predator or epidemiological problems, where the interactions between populations 
should be “balanced” (e.g., the number of newly infected individuals should be equal to 
decrease of the number of susceptible individuals). Nevertheless, the main ideas and 
techniques used in [1] can be applied to “balanced” inhomogeneous community models 
with slight modifications. 
 We do not develop here a general theory of such models; instead, we consider a 
model of a biological community composed of two interacting populations depending on 
parameters: 
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                            (A.2) 
 
assuming that parameters a and b are distributed. Here ,  are the population 
densities,  , ) are the total sizes of the cell 
populations.  Denote p
),( atx ),( bty
∫= A daatxtX ),()( ∫=
B
dbbtytY ),()(
1(t;a)=x(t,a)/X(t),  p2(t;b)=y(t,b)/Y(t)  the current probability 
density functions of corresponding parameters in uninfected and infected populations 
accordingly; then  
 ( ) ∫∫ == AAa daataptXdaataxtE ),()(),()( 1 , ( ) ∫∫ == BBb dbbtbptYdbbtbytE ),()(),()( 2  
 
are the current mean values of the parameters a and b . 
 We suppose that the initial population sizes and initial distributions of the 
parameters are given: 
 
),0(),0(     ),,0(),0( 2010 bpYbyapXax == . 
 
The particular form of system (A.2) is motivated by the models explored in the paper, 
which are special cases of (A.2).  
 Problem (A.2) can be reduced to the Cauchy problem for a certain system of ODE. 
Let 
 
  Ma(λ)= exp(λa)p∫
A
1(0, a)da,                                                      (A.3) 
 Mb(λ)= exp(λb)p∫
B
2(0, b )db        
 
be the mgfs (moment generating functions) of the initial probability densities p1(0,a) and 
p2(0,b).  
 Let us consider the system for auxiliary variables 
 
 dq10(t)/dt= q10(t)F1(X*,Y*, E1(t)), q11(0)=1;                                                      (A.4) 
 dq11(t)/dt= G1(X*,Y*, E1(t)), q11(0)=0;  
 dq20(t)/dt= q20(t) F2(X*,Y*, E2(t)), q20(0)=1;  
 dq21(t)/dt= G2(X*,Y*, E2(t)), q21(0)=0. 
 
The functions X*(t), Y*(t) and Ei(t) are defined by the formulas 
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 X*(t)= X(0) q10(t) Ma(q11(t)), Y*(t)= Y(0) q20(t) Mb(q21(t)). 
 
 Theorem 1. Let Cauchy problem (A.4)-(A.5) have a unique global solution {q ji(t)} 
at t∈[0,T) where 0≤T≤∞. Then the functions 
 
x(t,a) = x(0,a) q10(t) exp[a q11(t)],                                                  (A.6) 
                 y(t,b) = y(0,b) q20(t) exp[b q21(t)],  
                 X(t) = X(0) q10(t) Ma(q11(t)), 
                Y(t) = Y(0) q20(t) Mb(q21(t)) 
 
satisfy system (A.2) at t∈[0,T).  
 Conversely, if  x(t,a), y(t,b), and X(t)= x(t;a)da, Y(t) = y(t;b)db  satisfy system 
(A.2) at t∈[0,T), then Cauchy problem (A.4) has a global solution {q
∫
A
∫
B
 j
i
 (t)} at t∈[0,T) and 
these functions can be written in the form (A.6) at t∈[0,T). 
Proof. 
Let {qij(t)}be a solution of  Cauchy problem (A.4)-(A.5) at t∈[0,T). According to 
system (A.4),  
 
dx(t,a)/dt= x(0, a) exp[a q11(t)] {dq10(t)/dt + q10(t)a dq11(t)/dt} = 
          x(t,a){F1(X*,Y*, E1(t)) + a G1(X*,Y*, E1(t))] ; 
dy(t,b) /dt= y(0, b) exp[bq21(t)] {dq20(t)/dt + q20(t)bdq21(t)/dt} = 
                       y(t,b){F2(X*,Y*, E2(t)) + bG2(X*,Y*, E2(t))]. 
 
Next, 
 
∫
A
x(t;a)da= x(0,a) exp[a q∫
A
1
1(t)] da=X(0) Ma(q11(t)); 
∫
B
y(t;b)db= y(0,b) exp[b q∫
B
2
1(t)] db =Y(0) Mb(q21(t)). 
 
Hence, the functions defined by (A.6), are connected by the relations 
 
X(t)=
 
x(t,a)da, Y(t)=
 
y(t;b)db. ∫
A
∫
B
 
 To complete the proof of the first part of the theorem, we have to determine the 
current parameter distributions,  and , and show that  E),(1 atp ),(2 btp i(t) defined by 
(A.5) are equal to the current mean values of the parameters, i.e., 
Ea(t)= =E∫A daatap ),(1 1(t) and Eb(t)=  =E∫B dbbtbp ),(2 2(t). For this, we need the following  
  
Proposition 1. Let the Cauchy problem (A.4)-(A.5) have a unique solution {qji(t)} at 
t∈[0,T). Then, for all t∈[0,T), 
1) the current parameter distributions,  and  are equal to ),(1 atp ),(2 btp
 
      =  exp[a q),(1 atp ),0(1 ap
1
1(t)] / Ma(q11(t)),                                                     (A.7) 
      =  exp[b q),(2 btp ),0(2 bp
2
1(t)] / Mb(q21(t));   
 
2) the moment generation functions of   and  are equal to ),(1 atp ),(2 btp
 
   Ma(t; λ)= Ma(λ+q11(t)) / Ma(q11(t)),                                                     (A.8) 
  Mb(t; λ)= Mb(λ+q21(t)) / Mb(q21(t)) 
 
 where Ma(λ), Mb(λ) are the mgf of initial distributions (A.3). 
Proof. 
 By definition,  = x(t,a)/X(t),  = y(t, b)/Y(t). According to (A.6), ),(1 atp ),(2 btp
 
),(1 atp = x(0,a) q
1
0(t) exp[a q11(t)] / X(t). 
 
Further, X(t) = X(0) q10(t) Ma(q11(t)) by (A.5), so 
 
),(1 atp =  exp[a q),0(1 ap
1
1(t)] / Ma(q11(t)). 
 
Similarly, =  exp[b q),(2 btp ),0(2 bp
2
1(t)] / Mb(q21(t)). Next, 
 
Ma(t; λ)=
 
exp(λa) da= {
 
exp[(λ+q∫
A
),(1 atp ∫
A
1
1(t))a] da}/ M),0(1 ap a(q
1
1(t)) = 
                       Ma(λ+q11(t)) / Ma(q11(t)); 
 
Similarly, Mb(t; λ)= Mb(λ+q21(t)) / Mb(q21(t)), as desired. 
 Now we are able to complete the proof of part 1 of Theorem:  
 
Ea(t)= =∂ M∫A daatap ),(1 a(t; λ) /∂λ│λ=0=[∂Ma(λ+q11(t)) /∂λ│λ=0] / Ma(q11(t)), 
 
and the last expression coincides with the formula (A.5) for E1(t).  
 Similarly, Eb(t)= ∂ Mb(t; λ) /∂λ│λ=0=[∂Mb(λ+q21(t)) /∂λ│λ=0] / Mb(q21(t)). 
 Let us prove now part 2 of Theorem; let x(t, a), y(t,b), and  X(t)= x(t;a)da, Y(t) = 
y(t;b)db  satisfy system (A.2) at t∈[0,T), so that   
∫
∫
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where 
 ( ) )(),()( tXdaataxtE
Aa ∫= , ( ) )(),()( tYdbbtbytE Bb ∫= . 
 
Let us temporarily define the functions  
q10(t) = exp[ F∫t
0
1(X(s),Y(s),Eb(s))ds],  q11(t) = G∫t
0
1(X(s),Y(s), Eb(s)) ds, 
q20(t) = exp[ F∫t
0
2(X(s),Y(s),Ea(s))ds],  q21(t) = G∫t
0
2(X(s),Y(s), Ea(s)) ds, 
 
Then  
 
dx(t, a)/ x(t,a) = dq10(t)/ q10(t) + adq11(t), 
dy(t, b)/ y(t,b) = dq20(t)/ q20(t) + bdq21(t); 
 
hence 
  
ln x(t,a) = lnq10(t) + aq11(t) +C1
ln y(t, b) = ln q20(t) + bq21(t) + C2 
 
where C j do not depend on t. 
Taking C 1 =ln x(0,a), C 2 =ln y(0,b) we obtain that 
 
x(t,a) = x(0,a) q10(t) exp[bq11(t)], 
y(t, b) =  y(0,b) q20(t) exp[bq21(t)]. 
 
Hence  
 
X(t)≡ x(t,a)da= x(0,a) q∫ ∫ 10(t) exp[bq11(t)] da=X(0) q10(t) Ma(q11(t)), 
Y(t)≡ y(t,b)db= y(0,b) q∫ ∫ 20(t) exp[bq21(t)]db =Y(0) q20(t) Mb(p21(t))  at t∈[0,T). 
 
From the definition, {qij(t)} is a solution of  Cauchy problem (A.4)-(A.5) for t∈[0,T). 
The proof is completed. 
 
Corollary.  System (A.2) is equivalent to the following non-autonomous system of 
ODEs: 
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where the mean parameter values are  
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where Ma(λ) and Mb(λ) are the mgf of the given initial pdfs , and the 
auxiliary variables q
),0( and ),0( 21 bpap
1(t), q2(t) can be found from the system 
 
 0)0( ,0)0(     )),(,,(     )),(,,( 212211 ==== qqtEYXGdt
dqtEYXG
dt
dq
ba .         (A.11) 
 
Proof.  
 It is enough to prove that system (A.9)-(A.11) is equivalent to (A.4)-(A.5). 
 Let Cauchy problem (A.4)-(A.5) have a unique global solution {q ji(t)} at t∈[0,T).  
Then, according to Theorem 1, functions (A.6) solve (A.2); it is easy to check that X(t) = 
X(0) q10(t) Ma(q11(t)), Y(t) = Y(0) q20(t) Mb(q21(t)) solve (A.9) and the definitions of the 
auxiliary variables and mean values of the parameters coincide with (A.10)-(A.11).  
 Conversely, let X(t), Y(t), q1(t), q2(t) solve (A.9)-(A.11) at t∈[0,T). Let q11(t) = q1(t),  
q21(t) = q2(t) and 
 
q10(t)=exp[ F∫t
0
1(X(s),Y(s),Eb(s))ds], q20(t)=exp[ F∫t
0
2(X(s),Y(s),Ea(s))ds]. 
 
Then {qji(t)} is a solution of Cauchy problem  (A.4)-(A.5); according to Proposition 1, 
the mgfs of the current distributions are given by (A.8) and mean parameter values (A.10) 
coincide with that defined by formulas (A.5).  Q.E.D. 
 
Proposition 1 allows one to determine the evolution of any initial parameter 
distribution with known mgf.  
 Example. Let parameter a have the Γ-distribution at the initial instant with 
coefficients s, η, k:  
 
P(0,a)= sk (a - η)k-1exp[-(a - η)s]/Γ(k), 
 
with the mean μ= η + k /s, the variance σ 2 = k /s2 and the mgf  Ma(λ) = exp(λη) /(1-λ/s) k. 
Then at any time moment t<T 
 
Ma(t; λ)= Ma(λ+q1(t)) / Ma(q1(t))=  exp(λη) /(1-λ/(s- q1(t)) k , 
 
i.e., the parameter a has again the Γ-distribution at t moment with coefficients s-q1(t), η, 
k. Next,  
 
∂M (λ+q1(t)) /∂λ│λ=0 / M(q1(t))=k/(s-q1(t))+η. 
 
Hence, the current mean of the parameter is  
 
η+−= )()( 1 tqs
ktEa                                          (A.12) 
 
where the auxiliary variable q1(t) is defined by (A.11). 
 As a particular inhomogeneous community model let us consider system (7): 
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 Suppose that,  at the initial moment, both parameters β and δ have the Γ-distribution 
with coefficients s1, η1, k1 and s2, η2, k2, respectively. Then the current mean parameter 
values are given by (A.12) and, finally, system (7)-(8) is reduced to the following system 
of ODEs: 
 
 ,1     , 21 −=+−= dt
dq
YX
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dt
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